JAGX — Jaguar Health, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1585608 ·
Last close
$4.53
Market Cap
$23.41M
52W High
$1267.88
52W Low
$2.35
ADV30
4,268,181
Next earnings
2026-11-12
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 1,225,000 | 194,000 | -7,597,000 | -12,682,000 | 34,194,000 | 3,788,000 | 29,273,000 |
| Mar 2026 | 20,247,000 | 19,089,000 | 10,182,000 | 8,849,000 | 37,434,000 | 7,278,000 | 53,186,000 |
| Dec 2025 | 3,235,000 | 1,035,000 | -20,442,000 | -23,061,000 | 38,323,000 | 968,000 | 57,011,000 |
| Sep 2025 | 3,083,000 | 2,551,000 | -7,238,000 | -9,502,000 | 49,472,000 | 3,527,000 | 45,113,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-7,542,000
Investing CF
$-256,000
Financing CF
$12,089,000
CapEx
$-215,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1639.35
As of
2026-08-23
Balance + Analyst (yfinance extras)
Retained Earnings
$-391,067,000
Inventory
$7,819,000
Receivables
$280,000
ST Investments
—
EBIT TTM
$-35,087,000
Pretax Income TTM
$-34,678,000
Interest Exp TTM
$699,000
Analysts
—
Yahoo Snapshot (yfinance, live)
Total Revenue
$27,815,000
EBITDA
$-23,193,000
Free Cash Flow
$-1,778,125
Enterprise Value
$14,444,846
Total Cash
$3,788,000
Total Debt
$16,651,000
Shares Out
5,168,300
Trailing EPS
$98.20
Book Value
$1.36
ROE
-548.8%
ROA
-38.0%
Div Yield
—
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 11,511,000 | -45,108,000 | -53,434,000 | 38,323,000 | 57,011,000 | -17,289,000 | -23,686,000 |
| Dec 2024 | 11,689,000 | -30,831,000 | -38,492,000 | 53,425,000 | 46,931,000 | 7,285,000 | -29,384,000 |
| Dec 2023 | 9,761,000 | -33,920,000 | -41,300,000 | 50,763,000 | 45,866,000 | 4,961,000 | -33,242,000 |
| Dec 2022 | 11,956,000 | -34,415,000 | -47,454,000 | 47,452,000 | 48,808,000 | -657,000 | -33,104,000 |
| Dec 2021 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
$29,569,000
NetIncome TTM
$-50,126,000
OpCashFlow TTM
—
Assets (Latest)
$37,434,000
Forward EPS
$-5.68
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| OPTH | Optimi Health Corp. | $23.39M | $4.09 | — |
| TXMD | TherapeuticsMD, Inc. | $23.26M | $2.01 | — |
| KYNB | KYNTRA BIO, INC. | $24.13M | $5.96 | — |
| ATOS | ATOSSA THERAPEUTICS, INC. | $24.15M | $2.42 | — |
| AYTU | AYTU BIOPHARMA, INC | $22.28M | $2.05 | — |
News headlines (Yahoo Finance, 1h cache)
Jaguar Health Targets Mid-2027 MVID NDA Filing as Crofelemer Intestinal Failure Program Advances
2026-10-06 14:53 · Yahoo
Napo Pharmaceuticals, a Jaguar Health Family Company, Sponsoring Intestinal Failure Panel Discussion at Pediatric Gastroenterology Conference in Abu Dhabi
2026-10-06 13:00 · Yahoo
Jaguar Health Announces a Special Stock Dividend
2026-10-03 00:35 · Yahoo
Jaguar Health Soars 32% as Rare-Disease Pipeline News Meets Thin Post-Split Float
2026-09-25 14:49 · Yahoo
Jaguar Health Receives Fee Waivers from FDA
2026-09-22 13:05 · Yahoo
Jaguar Health, Inc. Announces Reverse Stock Split
2026-09-15 13:00 · Yahoo
All Randomized Pediatric Patients to Continue in the Single-Blind Extension Phase of Jaguar Health's Pivotal Clinical Trial of Crofelemer for Microvillus Inclusion Disease (MVID) with Intestinal Failu
2026-09-10 13:00 · Yahoo
Jaguar Health Launches Neonorm Dog on Amazon, Expanding Animal-Health Product Franchise
2026-09-08 15:06 · Yahoo
Now Available on Amazon: Neonorm Dog, Jaguar Health's Non-Prescription Product for Support of Normal Stool Consistency and GI Fluid Balance in Dogs
2026-09-08 13:00 · Yahoo
Additional Infant Patient to Receive Jaguar Health's Crofelemer for Compassionate Use for Treatment of Intestinal Failure (IF)
2026-09-04 12:30 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.